comparemela.com

Keith Kaye News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Antibiotic Combination for Complicated UTIs

Cefepime-enmetazobactam beat piperacillin-tazobactam in phase III study

New brunswickNew jerseyUnited statesRutgers universityMike bassettKeith kayeAcute pyelonephritis

Sulbactam-Durlobactam FDA-Approved for Bacterial Pneumonia

Trade name Xacduro is an antibiotic meant to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii.

Peter kimKeith kayeAntimicrobial drugs advisory committeeDivision of antiDivision of allergyDrug evaluationDrugs advisory committeeLancet infectiousInfectious diseasesRutgers robert wood johnson medical

New antibiotic may soon treat scary ABC pneumonia

The combo antibiotic sulbactam-durlobactam fights dangerous pneumonia at least as well as the best currently approved treatment, a trial shows.

Keith kayeDivision of allergyDrug administrationAntimicrobial drugs advisory committeeInfectious diseaseRobert wood johnson medical schoolLancet infectiousDrugs advisory committee

Could FDA recommend new antibiotic for often-fatal pneumonia?

A new combination antibiotic for hospital-acquired pneumonia offers advantages in dosing and tolerability, a Phase III trial has shown.

Keith kayeAntimicrobial drugs advisory committeeDrug administrationDivision of allergyLancet infectious diseasesInfectious diseaseRobert wood johnson medical school

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by. | May 11, 2023

United statesKeith kayeCenters for diseaseDrug administrationExchange commissionInnoviva incDivision of allergyEntasis therapeutics incSecurities exchangeGlaxo group limitedAntimicrobial drugs advisory committeeJolla pharmaceutical companyWorld health organizationInnoviva specialty therapeuticsLancet infectious diseasesSerious infections

vimarsana © 2020. All Rights Reserved.